Splicing-directed therapeutic strategies for pediatric high-grade glioma pediatric high-grade gliomas (PHGGS) harboring histone H3.3 G34R mutations lack effective targeted therapies and remain…
Active Grant Awarded
- Award ID
- RNS153327UNL5K1
- Recipient
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $620,480
Award facts
- Assistance listing
- 93.NS1 Neurosciences and Neurological Disorders – Research Projects (RP)
- Completion date 0% complete
- Place of performance
- Chicago, IL 60611, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute of Neurological Disorders and Stroke, awarded Northwestern University a grant with $620,480 obligated on November 17, 2026, under Assistance Listing 93.NS1, Neurosciences and Neurological Disorders – Research Projects (RP). The project develops antisense oligonucleotide (ASO)-based RNA splicing modulation as a treatment strategy for pediatric high-grade glioma harboring histone H3.3 G34R mutations. It targets the GTF2I-D isoform, which the source identifies as driving G34R tumor growth and stem-like properties. Stated objectives include defining how G34R-driven splicing reprogramming drives tumor malignancy and controls therapeutic response, and testing ASOs alone and in rational combination with CDK6 inhibitors and radiotherapy. Preliminary work reported that modulating the G34R-associated GTF2I-D isoform or ASOs targeting G34R-associated RNA-binding proteins suppressed tumorigenicity and enhanced inhibition by a CDK4/6 inhibitor and radiation therapy. The award runs from November 17, 2026 to an ultimate completion date of November 30, 2031, with place of performance in Chicago, Illinois 60611. The award is classified as a grant. The recipient's Sponsored Research Division holds the UEI KG76WYENL5K1. The program funds extramural NINDS research, including basic research on the structure and function of the brain and nervous system, with applications competing on merit for available funds.
Description
Splicing-directed therapeutic strategies for pediatric high-grade glioma pediatric high-grade gliomas (PHGGS) harboring histone H3.3 G34R mutations lack effective targeted therapies and remain highly refractory to current treatment regimens, underscoring the need for new therapeutic modalities and rational combination strategies. We propose RNA splicing modulation as a new therapeutic modality for G34R phgg and develop an antisense oligonucleotide (ASO)-based treatment strategy to therapeutically suppress oncogenic splicing programs. In our preliminary studies, we identify RNA alternative splicing as a core, mechanistically targetable therapeutic vulnerability in G34R phgg. Through integrative analysis of bulk and single-cell transcriptomes, we identify a therapeutically actionable splicing dependency that can be directly targeted for treatment development. We show that a top G34R-associated as event, the transcription factor tfii-I (GTF2I) that produces an oncogenic GTF2I-Δ isoform drives G34R tumor growth and stem- like properties. We identify druggable splicing regulators that enable therapeutic modulation of oncogenic splicing programs to selectively induce the oncogenic GTF2I-Δ isoform. Modulation of the G34R-associated GTF2I-Δ isoform or antisense oligonucleotides (ASOS)-targeting G34R-associated RBP suppressed phgg tumorigenicity and enhanced therapeutic inhibition by CDK4/6 inhibitor and radiation therapy. These findings establish aberrant RNA splicing as a mechanistically actionable therapeutic vulnerability in G34R phgg. The overall goal of this project is to define how G34R-driven splicing reprogramming renders phgg tumor malignancy and controls therapeutic response and to develop splicing-directed treatment strategies using antisense oligonucleotides (ASOS), alone and in rational combination with CDK6 inhibitors and radiotherapy. This project establishes RNA splicing modulation as a novel therapeutic platform for pediatric brain tumors and provides a preclinical framework for translating splicing-directed therapies into combination treatment regimens for refractory phgg.
Quick answers
Who received award RNS153327UNL5K1?
RNS153327UNL5K1 was awarded to Northwestern University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on November 17, 2026.
How much is award RNS153327UNL5K1 worth?
$620,480 has been obligated on RNS153327UNL5K1.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award